...two topical peptide-based therapeutics in the clinic for infectious disease that are not conventional antibiotics. Pergamum AB...
...National Cancer Institute (NCI), Bethesda, Md. National Eye Institute, Bethesda, Md. NovaBiotics Ltd., Aberdeen, U.K. Pergamum AB...

...to placebo (p<0.05), while high-dose LL-37 led to no improvement in wound healing vs. placebo. Pergamum...
...said it does not plan to finance further clinical development of LL-37 without a partner. Pergamum AB...

...sheath and around the tendon sheath after surgery but before closure of the surgical wound. Pergamum...
..."confidence to proceed with the development" of PXL-01, but declined to disclose details. Last year, Pergamum...
...of improving TAM2 scores at week 12 post-surgery vs. placebo (see BioCentury, July 16, 2012). Pergamum AB...

...evaluating 3 doses of LL-37 for 1 month in 34 patients with venous leg ulcers. Pergamum AB...

...up to Phase II testing. The companies will share global rights to market the product. Pergamum...
...additional details. Cadila could not be reached for comment. Cadila Pharmaceuticals Ltd. , Ahmedabad, India Pergamum AB...

...Sweden Business: Neurology Hired: Jan Nilsson, a director, as COO, formerly chief commercial officer of Pergamum AB...

...Mood AB ; infectious disease companies Biosergen A/S and Dilaforette AB ; and dermatology play Pergamum AB...
...NeoDynamics AB , Lidingo, Sweden Nordic Biotech , Copenhagen, Denmark NovaSaid AB , Solna, Sweden Pergamum AB...

...DPK-060 led to complete cure in 85-94% of patients depending on the rating scale used. Pergamum...
...in 13 of the 25 portfolio companies of Karolinska Development AB (SSE:KDEV, Solna, Sweden), including Pergamum...
...Omnio Healer AB, BioCis Pharma Ltd. and PharmaSurgics into Pergamum (see BioCentury, Sept. 14, 2009). Pergamum AB...

...Dilafor AB , Biosergen A/S , NeoDynamics AB , Clanotech AB, Promimic AB , Pergamum AB...

...Phase I/II trial to evaluate 3 doses of LL-37 for 1 month in 32 patients. Pergamum AB...